Compound learning guide · KPV
A three-letter peptide sits behind a growing list of gut, skin and inflammation claims. Understanding KPV starts with a more useful question: which material was tested, in what model, and what actually changed?
KPV is a three-amino-acid peptide: lysine–proline–valine. Its sequence comes from the end of alpha-MSH, a longer signaling peptide. KPV research includes intestinal cells, animal inflammation models and engineered delivery systems. Those findings do not yet establish a benefit, dose or safety profile in people.
This guide explains the gut and oral studies, separates KPV from similar names, and examines the evidence behind common side-effect, cancer and weight questions.
What is KPV peptide?
KPV names the sequence Lys-Pro-Val, corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. A three-residue peptide is called a tripeptide. The letters describe its amino acids; they do not specify every chemical feature of a supplied material.
Identity field notes
Three residues. Check the complete material.
Free-acid KPV has the molecular formula C16H30N4O4 and a molecular weight of approximately 342.43 g/mol.
Sequence schematic, not an exact molecular structure or a lot specification. Acetylation, amidation, a counterion or chemical conjugation changes the material being described.The PubChem KPV record describes the free-acid form. KPV acetate, KPV amide and a KPV-containing delivery system should not inherit that material description without checking their actual composition. The FDA’s 2026 KPV evaluation also distinguishes the free-base and acetate descriptions in the nomination it reviewed.
Is KPV the same as alpha-MSH?
No. KPV is a short sequence from the parent peptide, not the complete 13-residue hormone. It cannot inherit every alpha-MSH receptor, pigmentation or physiological claim simply because those three residues match.
In a 2003 mouse inflammation study, KPV activity persisted in a model with a nonfunctional MC1 receptor and was not blocked by the study’s MC3/MC4 antagonist. In the accompanying macrophage experiments, KPV did not reproduce the cAMP and cytokine effects seen with the comparison melanocortins. These are model-specific observations, not a universal receptor map. Getting et al., 2003.
Reviews from 2003, 2007, 2008 and 2010 provide background on this peptide family. They are useful starting points for finding original experiments; four reviews do not amount to four independent human trials.
How does KPV work in laboratory studies?
Two recurring ideas are entry into particular cells and changes in inflammatory signaling. PepT1 is a transporter that can move small peptides into cells. NF-κB is a signaling system involved in switching inflammatory genes on. Neither term, by itself, tells us whether a person will feel better.
In the foundational intestinal work, KPV reduced inflammatory signaling in human-derived intestinal and immune cell lines. The researchers used transporter-negative cells, introduced PepT1 and applied a competing transporter substrate to test the uptake explanation. Those controls support a PepT1-dependent effect in the tested systems. Dalmasso et al., 2008.
A separate study used human-derived bronchial cells exposed to inflammatory stimuli. It reported changes in NF-κB nuclear transport and proposed an importin-related explanation. A bronchial-cell experiment is evidence about that model; it does not establish a respiratory treatment or a mechanism operating identically in every tissue. Land, 2012.
What does KPV research show about gut health and oral delivery?
Gut research is an important part of the KPV literature, but “oral KPV” covers experiments with very different materials. Free peptide, a peptide inside a carrier and a chemically modified prodrug cannot be treated as interchangeable.
Intestinal cells and experimental colitis
The PepT1 study also reported reduced inflammation in two mouse colitis models after oral KPV exposure. A separate mouse study examined chemically induced and immune-cell-transfer colitis, reporting improved inflammatory measures and recovery of lost weight. Recovery from experimental illness is not evidence of a human weight-gain effect. Dalmasso et al.; Kannengiesser et al..
A carrier changes the experiment
Researchers packaged KPV in hyaluronic-acid-functionalized nanoparticles within a hydrogel for mouse colitis research. The result belongs to that delivery system. Even within the study, the comparison between targeted and non-targeted nanoparticles was not significant for every inflammatory endpoint. Xiao et al., 2017.
A combination includes another active drug
A newer nanoparticle approach combined KPV with tacrolimus, also called FK506. Treatment was intravenous in these mouse comparisons, not an oral-delivery test. Its reported intestinal-barrier and inflammatory results cannot be assigned to isolated KPV or used to claim that KPV replaces immunosuppressive treatment. Zhang et al., 2024.
proKPV is a chemically engineered material
A study linked KPV to a responsive scaffold with a PEG component, producing self-assembling proKPV nanoparticles. In the tested mouse design, the engineered material improved colitis outcomes while the stated free-KPV comparison did not reproduce that benefit. This supports studying delivery chemistry, not assuming the same result for an ordinary capsule. Cheng et al., 2026.
What does the 2026 “3.8-fold” result mean? It compared the area under a fluorescent-label signal-versus-time curve in inflamed mouse colon for labeled proKPV versus labeled KPV. It was not a measurement of intact KPV in human blood, a clinical response rate or a proven increase in an oral product’s bioavailability.
Does oral KPV work in people? These experiments do not answer that question. Formulation, protection from breakdown, tissue exposure and clinical outcomes each need their own evidence.
What about skin, antimicrobial and weight claims?
Research beyond the gut is real, but the word “benefit” can hide the difference between a cell measurement and an outcome in people. Here are three examples worth separating.
Skin cells and excised skin
A 2025 study examined particulate-stressed keratinocytes and a three-dimensional skin model, reporting changes in viability, oxidative stress and inflammatory signaling. It did not test treatment of acne, eczema or rosacea in patients. Sung et al., 2025.
A separate delivery study used excised human skin. Passive transport was below its assay’s detection limit, while device-assisted methods changed transport. Human tissue outside the body is not a trial of a topical KPV product in people. Pawar et al., 2017.
Antimicrobial results depend on the assay
An early study reported antimicrobial activity of alpha-MSH peptides, including KPV, in bacterial and yeast experiments. Cutuli et al., 2000.
A later study of acetylated, amidated KPV and modified analogues found no antimicrobial activity under its tested conditions, while examining resistance to enzymatic breakdown. The material and assay matter. Neither paper establishes a human infection treatment. Songok et al., 2018.
Does KPV cause weight loss or weight gain?
A 2026 study reported approximately 55% lower lipid staining and 38% lower intracellular triglyceride in a mouse-derived fat-cell model under a tested KPV condition. Those numbers describe cells, not percentage body-fat loss. The same paper included a high-fat-diet mouse arm with lower weight gain and adipose-tissue measures; it did not study human weight management. An et al., 2026.
A separate 2026 paper studied lipid accumulation in HepG2 liver-derived cells. That is not evidence of reduced liver fat or treatment of liver disease in people. Lee et al., 2026. Neither these results nor weight recovery in a colitis experiment provides a reliable prediction of weight change for an individual.
How strong is the evidence for KPV benefits?
The clearest support is preclinical: specific cell systems, animal models and experimental delivery formulations. A useful assessment keeps the study material, comparison and endpoint together. It also keeps negative results visible.
Has KPV been studied in humans?
Read the word “human” carefully
- Human-derived cellsIntestinal, bronchial and skin-cell experiments can examine mechanisms. They do not measure clinical benefit or side-effect frequency.
- Human tissue samplesExcised skin and biopsy measurements answer tissue questions. They do not mean study participants received KPV.
- People given the actual compoundThis is the evidence needed to establish human exposure and clinical outcomes. The FDA’s 2026 review did not identify human KPV exposure data.
Our September 8, 2026 ClinicalTrials.gov searches for KPV and Lys-Pro-Val returned no matching records; name searches can miss differently indexed or unpublished work. The more substantial finding is the FDA’s documented human-evidence gap in its KPV evaluation and current safety-risk record.
K(D)PT is not KPV. A published randomized ulcerative-colitis trial tested K(D)PT, a tripeptide with D-proline and threonine. KPV contains proline and valine. The trial’s results belong to K(D)PT and cannot fill the human-evidence gap for KPV. Kucharzik et al., 2017.
Does KPV cause cancer or prevent it?
The available research does not establish either a human cancer-prevention benefit or a human cancer-risk profile. One frequently cited 2016 paper illustrates why a broad claim would be misleading:
Inflammation-associated mouse model
Lower tumor burden
KPV reduced tumor measures in the study’s chemically induced, inflammation-associated model. The paper also examined PepT1 and human biopsy expression; those biopsy observations were not treatment of people with KPV.
Genetic APC mouse model
No reduction in tumor burden
In its separate APCMin/+ experiment, KPV did not reduce intestinal tumor burden, although an inflammatory marker decreased. Lower inflammation and lower tumor burden were different outcomes.
These are two experimental contexts from Viennois et al., 2016, not competing estimates of a clinical effect. Neither establishes cancer safety or a reason to replace cancer care.
What is known about side effects, safety and half-life?
The lack of established human exposure data means there is no dependable clinical frequency table for KPV side effects or a validated human dose, onset, cycle length or half-life. “No side effects reported” is not equivalent to a well-measured safety profile.
Laboratory stability studies can help characterize a material. For example, a validated chromatography study examined KPV degradation under chemical stress and identified a major degradation product. It did not establish a human elimination half-life or a universal vial shelf life. Pawar et al., 2015.
According to the FDA’s 2026 evaluation, KPV is not a component of an FDA-approved drug. Its July 2026 advisory-committee consideration is distinct from drug approval; advisory recommendations are nonbinding. This guide does not infer a final regulatory decision or legal access rule from the fact that a meeting occurred.
What should you check when comparing KPV research materials?
A research page should help distinguish materials before it points to an order. Start with the stated sequence, termini, salt or counterion, nominal amount and the actual lot documentation. A study’s modified formulation is not identified by the three letters KPV alone.
On a narrow screen, scroll this table horizontally. The final column explains the limit of each measurement.
| Question | Useful record | What it cannot establish alone |
|---|---|---|
| Which material is this? | Sequence, terminal groups, counterion and identity method. | Equivalence to an amidated peptide, conjugate or published delivery formulation. |
| What does the purity value mean? | Method, chromatogram and stated detector-area calculation. | Active mass per vial, sterility or suitability for human use. |
| Which lot was measured? | Report issuer, lot identifier, configuration, date and stated results. | That a displayed historical report necessarily identifies the lot currently shipping. |
| How should the material be stored? | Applicable documentation and a validated procedure for the actual preparation. | A universal number of days after reconstitution or a human half-life. |
See how to read a peptide certificate of analysis for method and reporting context. Apex’s KPV research-reagent specifications and available documentation provide the separate commercial record. This guide does not certify a newly supplied lot or turn a laboratory reagent into a finished clinical formulation.
Frequently Asked Questions about KPV
What is KPV peptide used for in research?
KPV is studied in inflammatory-signaling, intestinal, skin-cell and experimental delivery models. It is the tripeptide lysine–proline–valine. These research uses do not establish an approved treatment or a benefit in people.
What are the proven benefits of KPV?
Published experiments report effects in defined cells, animals and engineered formulations. The current evidence does not establish a proven clinical benefit for KPV in people. The material, model and measured endpoint should remain attached to each result.
Are there human clinical trials of KPV?
The FDA’s 2026 review did not identify human KPV exposure data. Our dated ClinicalTrials.gov name searches returned no matching KPV records. Human-derived cells and excised human skin are not patient trials, and the published K(D)PT trial studied a different tripeptide.
Does oral KPV work for gut health?
Mouse studies report intestinal effects, but oral experiments use different materials. The 2026 proKPV paper studied a chemically engineered nanoparticle system, not an ordinary free-KPV capsule. Those experiments do not establish a clinical gut-health benefit or an effective oral dose in people.
What are KPV’s side effects?
Reliable human side-effect frequencies and a long-term safety profile have not been established. Missing human exposure data should not be described as proof of good tolerance. A high chromatographic purity percentage cannot answer clinical safety questions.
Does KPV cause cancer or prevent cancer?
The available research does not establish a human cancer-risk profile or a cancer-prevention benefit. A 2016 mouse paper found lower tumor burden in one inflammation-associated model but no reduction in its genetic APC model. These model-specific results do not support a general cancer claim.
Does KPV cause weight loss or weight gain?
Recent cell and mouse studies measured lipid accumulation and weight-related outcomes, but they did not establish human weight loss. Weight regained during recovery from experimental colitis is a different endpoint. Neither result reliably predicts an individual’s weight response.
What is the half-life of KPV?
A validated human elimination half-life was not established in the evidence reviewed here. Chemical-stress stability, degradation in a laboratory fluid and tissue fluorescence from a labeled delivery system are different measurements. None supplies a universal human dosing interval.
How is KPV different from BPC-157?
KPV is a three-residue alpha-MSH-related sequence; BPC-157 is a different 15-residue peptide. Their study designs and evidence bases differ. Shared discussion of gut or inflammation research does not establish equivalent effects, a superior clinical choice or an effective combination.
Is KPV FDA approved?
The FDA’s 2026 evaluation states that KPV is not a component of an FDA-approved drug. Advisory-committee discussion about compounding is a separate process and does not itself constitute drug approval.
Continue your KPV research
KPV is one component of the KLOW blend. Evidence for an isolated component does not establish the behavior, stability or benefit of a mixture. The KLOW guide examines that distinction; the BPC-157 guide covers a different peptide and its own evidence.
References and source notes
Original studies and contextual reviews are identified below. Detailed claims above are linked to the relevant study; a review or a related molecule is not counted as a new KPV clinical trial.
- Cutuli M et al. (2000). Antimicrobial effects of alpha-MSH peptides.
- Getting SJ et al. (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.
- Luger TA et al. (2003). New insights into the functions of alpha-MSH and related peptides in the immune system. Contextual review.
- Luger TA et al. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Contextual review.
- Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
- Kannengiesser K et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
- Brzoska T et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Contextual review.
- Brzoska T et al. (2010). Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Contextual review.
- Land SC et al. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.
- Pawar KR et al. (2015). Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.
- Viennois E et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.
- Kucharzik T et al. (2017). Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study.
- Xiao B et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
- Pawar K et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
- Songok AC et al. (2018). Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue.
- Zhang D et al. (2024). PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.
- Sung J et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.
- Cheng J et al. (2026). Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.
- Lee JY et al. (2026). Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.
- An SH et al. (2026). KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.
Research-use scope
This guide explains published research. It does not provide a treatment recommendation, personal dose, administration schedule or claim of clinical safety. Apex supplies research reagents for laboratory use; they are not for human consumption.
Reviewed by
Apex Laboratory Editorial Team
Reviewed by the Apex Laboratory Editorial Team. Prepared under Apex’s editorial standards, with review of compound identity, source-to-claim fit, human-study distinctions and analytical limits. Source review: September 8, 2026. For a correction or a source question, contact Apex Laboratory.
